{"filing":{"accession_number":"0001193125-26-396690","cik":"0001370053","ticker":"ANAB","company_name":"ANAPTYSBIO, INC","form":"8-K","filing_date":"2026-09-21","report_date":"2026-09-21","primary_document":"anab-20260921.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1370053/000119312526396690/anab-20260921.htm"},"events":[{"id":34018,"run_id":31315,"accession_number":"0001193125-26-396690","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"AnaptysBio issued a press release on September 21, 2026, announcing financial results for the three months and transitional fiscal year ended June 30, 2026. The disclosure includes consolidated balance sheets, statements of operations, and comprehensive loss data, along with key financial metrics such as collaboration revenue of $27.5 million and $53.0 million for the three and six months ended June 30, 2026, and net income from continuing operations of $177.3 million and $176.4 million respectively. This is a standard earnings release disclosure under Item 2.02, material to investors assessing the registrant's financial performance and royalty-generating capacity from its Jemperli and Quimilza collaborations.","company_name":"ANAPTYSBIO, INC","ticker":"ANAB","filing_date":"2026-09-21","form":"8-K","submitted_at":null,"items":[{"id":37633,"accession_number":"0001193125-26-396690","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"AnaptysBio issued a press release on September 21, 2026, announcing financial results for the three months and transitional fiscal year ended June 30, 2026. The disclosure includes consolidated balance sheets, statements of operations, and comprehensive loss data, along with key financial metrics such as collaboration revenue of $27.5 million and $53.0 million for the three and six months ended June 30, 2026, and net income from continuing operations of $177.3 million and $176.4 million respectively. This is a standard earnings release disclosure under Item 2.02, material to investors assessing the registrant's financial performance and royalty-generating capacity from its Jemperli and Quimilza collaborations.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-21T20:22:17.828917+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":37633,"accession_number":"0001193125-26-396690","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"AnaptysBio issued a press release on September 21, 2026, announcing financial results for the three months and transitional fiscal year ended June 30, 2026. The disclosure includes consolidated balance sheets, statements of operations, and comprehensive loss data, along with key financial metrics such as collaboration revenue of $27.5 million and $53.0 million for the three and six months ended June 30, 2026, and net income from continuing operations of $177.3 million and $176.4 million respectively. This is a standard earnings release disclosure under Item 2.02, material to investors assessing the registrant's financial performance and royalty-generating capacity from its Jemperli and Quimilza collaborations.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-21T20:22:17.828917+00:00","company_name":"ANAPTYSBIO, INC","ticker":"ANAB","filing_date":"2026-09-21"}]}